Apyx Medical Corp: Form 10-K for the period ended Dec 31, 2014
Filed with the SEC on Feb 27, 2015 and accepted by EDGAR at Feb 27, 2015, 14:13 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-10-01 to 2014-12-31 | $7.5m | us-gaap:Revenues |
| Revenue | 12 months2014-01-01 to 2014-12-31 | $27.7m | us-gaap:SalesRevenueNet |
| Cost of revenue | 12 months2014-01-01 to 2014-12-31 | $18.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2014-10-01 to 2014-12-31 | $2.4m | us-gaap:GrossProfit |
| Gross profit | 12 months2014-01-01 to 2014-12-31 | $9.0m | us-gaap:GrossProfit |
| Research and development | 12 months2014-01-01 to 2014-12-31 | $1.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2014-01-01 to 2014-12-31 | $6.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2014-01-01 to 2014-12-31 | −$5.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2014-01-01 to 2014-12-31 | $4.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-10-01 to 2014-12-31 | −$5.5m | us-gaap:NetIncomeLoss |
| Net income | 12 months2014-01-01 to 2014-12-31 | −$17.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-10-01 to 2014-12-31 | −$0.31 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2014-01-01 to 2014-12-31 | −$1.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2014-01-01 to 2014-12-31 | −$1.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2014-01-01 to 2014-12-31 | 17,756 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2014-01-01 to 2014-12-31 | −$417.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2014-01-01 to 2014-12-31 | $630.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-12-31 | $5.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-12-31 | $15.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-12-31 | $24.8m | us-gaap:Assets |
| Current liabilities | At period end2014-12-31 | $3.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-12-31 | $20.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-12-31 | $1.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001477932-15-001424. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.